Nitrosamine

Abstract The presence of N-nitrosamine impurities and nitrosamine drug substance-related impurities (NDSRIs) in medicines poses a significant challenge not only for...

Abstract To prevent contamination by nitrosamine drug substance-related impurities (NDSRIs) in solid dosage forms, the modeling of drug nitrosation reactions...

See this article by Vikram Thermo: A Sudden Jolt: When the Medicine Became the Risk In July 2018, the pharmaceutical...

Abstract Nitrosamine impurities have provoked numerous global medicine recalls due to their possible presence during drug manufacturing or storage. Regarding...

Abstract NNitrosamine risk assessment and control are essential components of pharmaceutical drug development and product evaluation. Nitrites present in excipients...

BASF has news for drug formulators! They introduced a new ‘Nitrosamine Risk Assessment and Mitigation’ app in ZoomLab®, their Virtual...

Abstract N-nitrosamine compounds have long been known for their carcinogenic properties, but they came into the focus of the pharmaceutical...

Since 2018 the risk of nitrosamine impurities in medicinal products has become a critical concern for pharmaceutical manufacturers and regulators...

Abstract N-nitroso-bisoprolol (NBP) is a nitrosamine drug substance-related impurity (NDSRI) of bisoprolol, which is used to treat cardiac diseases since...

Abstract Nitrosamine impurities have garnered recent attention due to their presence in pharmaceuticals and their mutagenic risks. Recent studies have...